BRIEF—Achilles Therapeutics announces manufacturing expansion

UK biotech Achilles Therapeutics today announced clinical manufacturing expansion in the UK and the USA.

Achilles’ manufacturing facility at the Cell & Gene Therapy Catapult (Catapult) in Stevenage, UK, has received a manufacturing license from the Medicines and Healthcare products Regulatory Agency (MHRA).

Separately, the company has entered into a partnership agreement for clinical manufacturing with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization in King of Prussia, Pennsylvania, USA.

The additional peak annual capacity of up to 600 doses of the company’s personalized clonal neoantigen-reactive T cell product candidates, known as cNeT, will support clinical manufacturing in the two ongoing Phase I/IIa CHIRON and THETIS clinical trials in non-small cell lung cancer and melanoma, respectively.